Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Achim Rothe"'
Autor:
Sibylle C. Mellinghoff, Michael Hallek, Jonathan Carney, Michael von Bergwelt-Baildon, Achim Rothe, Christoph Scheid, Udo Holtick, Annika Y. Claßen
Publikováno v:
European Journal of Haematology. 104:291-298
Objective Fluconazole or posaconazole is a standard of care in antifungal prophylaxis for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). However, many patients need to interrupt standard prophylaxis due to intolerabili
Autor:
Hinrich P. Hansen, Peter Borchmann, Thomas C. Koslowsky, Andreas Engert, Elke Pogge Von Strandmann, Roland T. Ullrich, Katrin S. Reiners, Maike Sauer, Ron D. Jachimowicz, Lukas C. Heukamp, Michael Hallek, Sampurna Chatterjee, Paul J. Yazaki, Sven Borchmann, Jörg Keßler, Achim Rothe, Marie Madlener
Publikováno v:
International Journal of Cancer. 134:2829-2840
NKG2D, an activating receptor expressed on NK cells and T cells, is critically involved in tumor immunosurveillance. In this study, we explored the potential therapeutic utility of the NKG2D ligand ULBP2 for the treatment of colon carcinoma. To this
Autor:
Georg Kuhnert, Christoph Scheid, Deniz Kahraman, Sebastian Theurich, Stephanie Sasse, Carsten Kobe, Achim Rothe, Michael von Bergwelt-Baildon, Markus Dietlein, Alexander Drzezga
Publikováno v:
Leukemia & Lymphoma. 55:811-816
Brentuximab vedotin has emerged as a possible treatment option in patients suff ering from relapsed and refractory Hodgkin lymphoma (HL). We investigated the role of 18fl uorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
Autor:
Helen Görgen, Peter Borchmann, Oliver Schmalz, Annette Pluetschow, Bastian von Tresckow, Eckhart Weidmann, Andreas Engert, Richard Greil, Michael Fuchs, Achim Rothe, Volker Diehl, Christian Junghanß, Boris Böll, Mario Bargetzi, Dennis A. Eichenauer, Hans Theodor Eich, Alexander Scherpe
Publikováno v:
Journal of Clinical Oncology. 31:1522-1529
Purpose Older patients with Hodgkin lymphoma (HL) account for approximately 20% of all HL patients. ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard of care in these patients. However, little is known o
Autor:
Bastian von Tresckow, Georg Kuhnert, Andreas Engert, Boris Böll, Achim Rothe, Helen Goergen, Dennis A. Eichenauer, Ulrich Jäger, Stephanie Sasse, Stephan Kreher, Andreas Lohri, Christopher Bangard
Publikováno v:
Leukemia & Lymphoma. 54:2144-2148
Only limited data are available on the role of brentuximab vedotin (SGN-35) in transplant-naive relapsed or refractory patients with Hodgkin lymphoma (HL). We thus retrospectively analyzed 14 patients with primary refractory or relapsed HL who were t
Publikováno v:
Nature Clinical Practice Rheumatology. 4:605-614
Rheumatic diseases are typified by aberrant cellular immune responses. The advent of antibody engineering has now led to the development of anti-inflammatory therapy to target these responses. In this Review, Rothe and colleagues highlight advances i
Autor:
Achim Rothe, Peter J. McKinnon, Peter Borchmann, Vijaya Lakshmi Simhadri, Andreas Engert, Bastian von Tresckow, Hinrich P. Hansen, Stephanie Sasse, Boris Böll, Venkateswara R. Simhadri, Michael Hallek, Katrin S. Reiners, Elke Pogge von Strandmann
Publikováno v:
Immunity. 27:965-974
SummaryThe activity of natural killer (NK) cells is regulated by surface receptors, which direct target cell recognition. NKp30 (Natural Cytotoxicity Receptor 3) induces target cell lysis and is also crucial for the interaction with dendritic cells.
Autor:
Barbara E. Power, Anne Nathanielsz, Frank Oberhäuser, Ralf J. Hosse, Achim Rothe, Elke Pogge von Strandmann, Peter J. Hudson, Andreas Engert
Publikováno v:
Journal of Biotechnology. 130:448-454
Engineered antibodies have become an invaluable source of biopharmaceuticals against a wide range of diseases. About 200 antibody-based biologicals have been tested in clinical trials. Single chain variable fragments of antibodies (scFvs) provide bin
Publikováno v:
Trends in Biotechnology. 24:587-592
IVC ( in vitro compartmentalization) provides a complete cell-free approach for the production of novel targeted proteins. IVC uses aqueous droplets, which contain DNA and components for protein production, within water-in-oil emulsions. Recent advan
Publikováno v:
Expert Opinion on Biological Therapy. 6:177-187
Ribosome display presents an innovative in vitro technology for the rapid isolation and evolution of high-affinity peptides or proteins. Displayed proteins are bound to and recovered from target molecules in multiple rounds of selection in order to e